AKBA News

Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Announces Establishment of Rare Kidney Disease Pipeline

Q32 Bio Sells Complement Inhibitor ADX-097

ATTENTION Akebia Therapeutics, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights

Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Shareholders that lost money on Akebia Therapeutics, Inc.(AKBA) should contact Levi & Korsinsky about Securities Fraud Investigation - AKBA

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Akebia Therapeutics, Inc. (AKBA)